...

Interactive Tools

CD4+ Cell Count Thresholds for Initiating Antiretroviral Therapy

Launch Tool


Source: Earlier Initiation of Antiretroviral Therapy—An Appraisal of Emerging Data


This tool is designed to present the relevant studies which have informed the debate on when to start HIV antiretroviral therapy according to CD4+ cell count. You can also view a convenient graphical summary of the key data from those studies and print the data and/or download corresponding slides.



Format: HTML | Date posted: 5/20/2010


Choosing First-Line Antiretroviral Therapy

Launch Tool


Source: When to Start, What to Use: A Master Class in the Use of First-Line Antiretroviral Therapy


Considering the efficacy, safety, and tolerability factors in determining the appropriate antiretroviral components for your patient’s initial HAART regimen?

 

This tool enables you to review data from controlled studies on the DHHS and IAS-USA preferred antiretroviral regimens for initial antiretroviral therapy. You can also view a convenient graphical summary of the key data from those studies and print the data and/or download corresponding slides.


Format: Adobe Flash (.swf) | File size: 140 KB | Date posted: 12/6/2007


Lipid Effects of Antiretroviral Therapy

Launch Tool


Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies


Understanding the potential for dyslipidemia or other cardiovascular risk factors while determining an appropriate HAART regimen

 

This tool enables you to review data from controlled studies on the lipid effects of recommended antiretroviral regimens for initial therapy as well as ‘switch strategies’ in patients on suppressive antiretroviral therapy.

 

You can also view a convenient graphical summary of the key data from those studies and print the data and/or download corresponding slides.


Format: HTML | Date posted: 1/12/2007


Fine-Tuning Antiretroviral Therapy

Launch Tool


Source: Fine-Tuning Antiretroviral Therapy in HIV-Infected Patients With Virologic Suppression: Strategies to Address Toxicity, Convenience, and Quality of Life


Considering switching a virologically suppressive antiretroviral regimen and want to know the key data associated with the specific switch?

 

This tool enables you to select specific switches that have been evaluated in controlled studies and then view a convenient graphical summary of the key data from those studies. You can also print the data and/or download slides.


Format: HTML | Date posted: 12/15/2006


Selecting a Boosted PI for the Treatment-Experienced Patient

Launch Tool


Source: Strategies for the Management of Multiclass-Resistant Patients


The tool is designed to provide easy access to data on the characteristics and suitability of the available boosted PIs as potential components of regimens for treatment-experienced patients, using data from prescribing information, clinical studies, and the expert opinion of the author, Joseph J. Eron, Jr, MD


Format: Adobe Flash (.swf) | File size: 76 KB | Date posted: 9/2/2005


Selecting an NRTI Backbone: An Interactive Tool

Launch Tool


Source: Optimizing the NRTI Backbone in HIV-Infected Patients Receiving Antiretroviral Therapy


This interactive tool is intended to help the user assess the characteristics of different NRTI backbones, according to criteria that have been selected for their potential relevance in specific clinical settings.


Format: Adobe Flash (.swf) | File size: 35 KB | Date posted: 8/24/2004


Neurologic Manifestations of HIV Infection


Faculty:

Katia Cikurel, MDLydia Estanislao, MDDavid M. Simpson, MD
  • Katia Cikurel, MD
  • Lydia Estanislao, MD
  • David M. Simpson, MD

Launch Tool


Source: Neurologic Aspects of HIV/AIDS: New Insights and Management Advances


An Interactive Decision Support Tool and Video Resource

A comprehensive guide to neurologic complications directly related to HIV infection of the central nervous system or to opportunistic diseases and neoplasms resulting from immune dysfunction. Browse the complications by name, or search them by presenting symptoms. Includes extensive video clips illustrating components of the neurologic examination, and classic presentations of specific complications.


Format: Adobe Flash (.swf) | File size: 59 KB | Date posted: 5/10/2004


Balancing the Risks vs the Benefit of HAART

Launch Tool


Source: Insulin Resistance and Body Shape Changes in HIV-Infected Patients


This interactive tool allows you to explore the balance between the potential benefits and cardiovascular risks of antiretroviral therapy in the background of various patient and treatment-related risk factors.


Format: Adobe Flash (.swf) | File size: 90 KB | Date posted: 4/22/2004


Impact of Different Interventions on Cardiovascular Risk in HIV-Infected Patients

Launch Tool


Source: Cardiovascular Risk Factors and Metabolic Complications in Patients Receiving HAART


An interactive resource that illustrates the impact of different interventions on the 10-year risk of cardiovascular disease in hypothetical patients with different baseline characteristics.


Format: Adobe Flash (.swf) | File size: 47 KB | Date posted: 4/21/2004


Algorithm for Management of Patients with Hyperlipidemia During PI-based Therapy

Launch Tool


Source: Cardiovascular Risk Factors and Metabolic Complications in Patients Receiving HAART


An interactive flowchart offering options for the clinical care of HIV-infected patients who experience protease inhibitor-associated hyperlipidemia.


Format: Adobe Flash (.swf) | File size: 15 KB | Date posted: 4/21/2004


Featured Content

Stay Tuned Volume 3: CME/CE-Certified Video

Stay Tuned Volume 3: CME/CE-Certified Video Explore the latest issues in HIV mgmt through streaming video & downloadable Podcasts.

2010 HIV/AIDS Annual Update

2010 HIV/AIDS Annual Update 5 interactive text modules outlining the year’s scientific and clinical advances.

Building a Bridge to Better HIV Care

Building a Bridge to Better HIV Care Review this guidelines-focused slideset on management of HIV across the treatment spectrum.